Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Inventiva ( (IVA) ) is now available.
On February 10, 2025, Inventiva reported its preliminary financial results for 2024, showing revenues of €9.2 million and cash reserves of €96.6 million by the end of the year. The company closed a structured financing deal for up to €348 million, with €116 million already secured. Inventiva announced a strategic focus on lanifibranor’s development, halting all other preclinical research and reducing its workforce by 50%. This move marks a pivotal shift in its operational strategy, potentially impacting stakeholders as the company gears up for possible marketing approvals and commercialization of lanifibranor.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company committed to developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other significant unmet medical needs. The company is advancing lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for MASH treatment. Inventiva boasts a robust scientific team and a proprietary molecule library, with operations anchored in its research and development facility.
YTD Price Performance: 13.64%
Average Trading Volume: 10,175
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $229.2M
See more data about IVA stock on TipRanks’ Stock Analysis page.
